Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Nov;63(Suppl 2):ii2–ii12. doi: 10.1136/ard.2004.029272

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

D Furst, F Breedveld, J Kalden, J Smolen, G Burmester, J Bijlsma, M Dougados, P Emery, E Keystone, L Klareskog, P Mease
PMCID: PMC1766772  PMID: 15479866

Full Text

The Full Text of this article is available as a PDF (130.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andonopoulos A. P., Meimaris N., Daoussis D., Bounas A., Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003 Nov;62(11):1116–1116. doi: 10.1136/ard.62.11.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anker Stefan D., Coats Andrew J. S. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002 Dec;86(2-3):123–130. doi: 10.1016/s0167-5273(02)00470-9. [DOI] [PubMed] [Google Scholar]
  3. Antoni Christian, Dechant Claudia, Hanns-Martin Lorenz P. D., Wendler Joerg, Ogilvie Alexandra, Lueftl Mathias, Kalden-Nemeth Dolores, Kalden Joachim R., Manger Bernhard. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506–512. doi: 10.1002/art.10671. [DOI] [PubMed] [Google Scholar]
  4. Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. doi: 10.1136/bmj.317.7152.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baert Filip, Noman Maja, Vermeire Severine, Van Assche Gert, D' Haens Geert, Carbonez An, Rutgeerts Paul. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601–608. doi: 10.1056/NEJMoa020888. [DOI] [PubMed] [Google Scholar]
  6. Baeten D., Kruithof E., Van den Bosch F., Van den Bossche N., Herssens A., Mielants H., De Keyser F., Veys E. M. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003 Sep;62(9):829–834. doi: 10.1136/ard.62.9.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bang Lynne M., Keating Gillian M. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121–139. doi: 10.2165/00063030-200418020-00005. [DOI] [PubMed] [Google Scholar]
  8. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  9. Birnbaum A. J., Gentile P. Treatment of myelodysplasia in a patient with active rheumatoid arthritis. Ann Intern Med. 2000 Nov 7;133(9):753–754. doi: 10.7326/0003-4819-133-9-200011070-00037. [DOI] [PubMed] [Google Scholar]
  10. Booth Anthony, Harper Lorraine, Hammad Tariq, Bacon Paul, Griffith Megan, Levy Jeremy, Savage Caroline, Pusey Charles, Jayne David. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004 Mar;15(3):717–721. doi: 10.1097/01.asn.0000114554.67106.28. [DOI] [PubMed] [Google Scholar]
  11. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., Rudwaleit M., Sieper J., Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. doi: 10.1002/art.11017. [DOI] [PubMed] [Google Scholar]
  12. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  13. Braun J., Pham T., Sieper J., Davis J., van der Linden Sj, Dougados M., van der Heijde D., ASAS Working Group International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817–824. doi: 10.1136/ard.62.9.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Breedveld F. C., Emery P., Keystone E., Patel K., Furst D. E., Kalden J. R., St Clair E. W., Weisman M., Smolen J., Lipsky P. E. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004 Feb;63(2):149–155. doi: 10.1136/ard.2003.013961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Brocq O., Plubel Y., Breuil V., Grisot C., Flory P., Mousnier A., Euller-Ziegler L. Switch étanercept--infliximab dans la polyarthrite rhumatoïde. 14 patients sur 132 traités par anti-TNFalpha. Presse Med. 2002 Nov 23;31(39 Pt 1):1836–1839. [PubMed] [Google Scholar]
  16. Cacoub Patrice, Lidove Olivier, Maisonobe Thierry, Duhaut Pierre, Thibault Vincent, Ghillani Pascale, Myers Robert P., Leger Jean Marc, Servan Jérôme, Piette Jean-Charles. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002 Dec;46(12):3317–3326. doi: 10.1002/art.10699. [DOI] [PubMed] [Google Scholar]
  17. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001 Dec;44(12):2933–2935. doi: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  18. Cauza Edmund, Spak Marita, Cauza Karla, Hanusch-Enserer Ursula, Dunky Attila, Wagner Ernst. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. 2002 Sep 4;22(6):227–232. doi: 10.1007/s00296-002-0246-3. [DOI] [PubMed] [Google Scholar]
  19. Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0. [DOI] [PubMed] [Google Scholar]
  20. Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0. [DOI] [PubMed] [Google Scholar]
  21. Clegg D. O., Reda D. J., Mejias E., Cannon G. W., Weisman M. H., Taylor T., Budiman-Mak E., Blackburn W. D., Vasey F. B., Mahowald M. L. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. doi: 10.1002/art.1780391210. [DOI] [PubMed] [Google Scholar]
  22. Culy Christine R., Keating Gillian M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 2002;62(17):2493–2537. doi: 10.2165/00003495-200262170-00013. [DOI] [PubMed] [Google Scholar]
  23. Cummins Carole, Connock M., Fry-Smith A., Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess. 2002;6(17):1–43. doi: 10.3310/hta6170. [DOI] [PubMed] [Google Scholar]
  24. Curran Shane A., FitzGerald Oliver M., Costello Patrick J., Selby Jeanette M., Kane David J., Bresnihan Barry, Winchester Robert. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol. 2004 Feb 1;172(3):1935–1944. doi: 10.4049/jimmunol.172.3.1935. [DOI] [PubMed] [Google Scholar]
  25. Davis John C., Jr, Van Der Heijde Désirée, Braun Jurgen, Dougados Maxime, Cush John, Clegg Daniel O., Kivitz Alan, Fleischmann Roy, Inman Robert, Tsuji Wayne. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230–3236. doi: 10.1002/art.11325. [DOI] [PubMed] [Google Scholar]
  26. Davis John, Jr, Webb Allison, Lund Steven, Sack Kenneth. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum. 2004 Apr 15;51(2):302–304. doi: 10.1002/art.20241. [DOI] [PubMed] [Google Scholar]
  27. De Rycke Leen, Kruithof Elli, Van Damme Nancy, Hoffman Ilse E. A., Van den Bossche Nancy, Van den Bosch Filip, Veys Eric M., De Keyser Filip. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003 Apr;48(4):1015–1023. doi: 10.1002/art.10876. [DOI] [PubMed] [Google Scholar]
  28. Doran Michele F., Crowson Cynthia S., Pond Gregory R., O'Fallon W. Michael, Gabriel Sherine E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287–2293. doi: 10.1002/art.10524. [DOI] [PubMed] [Google Scholar]
  29. Doran Michele F., Crowson Cynthia S., Pond Gregory R., O'Fallon W. Michael, Gabriel Sherine E. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2294–2300. doi: 10.1002/art.10529. [DOI] [PubMed] [Google Scholar]
  30. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  31. Elkayam Ori, Caspi Dan, Reitblatt Tatiana, Charboneau Darlene, Rubins Jeffrey B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004 Feb;33(4):283–288. doi: 10.1053/j.semarthrit.2003.10.003. [DOI] [PubMed] [Google Scholar]
  32. Elkayam Ori, Hawkins Philip N., Lachmann Helen, Yaron Michael, Caspi Dan. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002 Oct;46(10):2571–2573. doi: 10.1002/art.10581. [DOI] [PubMed] [Google Scholar]
  33. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  34. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  35. Feletar M., Brockbank J. E., Schentag C. T., Lapp V., Gladman D. D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004 Feb;63(2):156–161. doi: 10.1136/ard.2003.006775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Dougados M., Emery P., Gibofsky A., Kavanaugh A. F., Keystone E. C. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003 Nov;62 (Suppl 2):ii2–ii9. doi: 10.1136/ard.62.suppl_2.ii2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Furst D. E., Keystone E., Maini R. N., Smolen J. S. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999 Nov;38 (Suppl 2):50–53. [PubMed] [Google Scholar]
  38. Furst Daniel E., Schiff Michael H., Fleischmann Roy M., Strand Vibeke, Birbara Charles A., Compagnone Daniele, Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563–2571. [PubMed] [Google Scholar]
  39. Garrison L., McDonnell N. D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I65–I69. doi: 10.1136/ard.58.2008.i65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Genovese Mark C., Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. doi: 10.1002/art.10308. [DOI] [PubMed] [Google Scholar]
  41. Gladman Dafna D., Helliwell Philip, Mease Philip J., Nash Peter, Ritchlin Christopher, Taylor William. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004 Jan;50(1):24–35. doi: 10.1002/art.11417. [DOI] [PubMed] [Google Scholar]
  42. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  43. Gottenberg Jacques-Eric, Merle-Vincent Florence, Bentaberry Fabrice, Allanore Yannick, Berenbaum Francis, Fautrel Bruno, Combe Bernard, Durbach Antoine, Sibilia Jean, Dougados Maxime. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003 Jul;48(7):2019–2024. doi: 10.1002/art.11163. [DOI] [PubMed] [Google Scholar]
  44. Gottlieb Alice B., Chaudhari Umesh, Mulcahy Lisa D., Li Shu, Dooley Lisa T., Baker Daniel G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003 Jun;48(6):829–835. doi: 10.1067/mjd.2003.307. [DOI] [PubMed] [Google Scholar]
  45. Goupille P., Valat J. P. Sulfasalazine: a definitively efficient treatment for psoriatic arthritis. J Rheumatol. 1996 Apr;23(4):791–792. [PubMed] [Google Scholar]
  46. Gulli Salvatore, Arrigo Carlo, Bocchino Loredana, Morgante Lucia, Sangari Donatella, Castagna Irene, Bagnato Gian Filippo. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003 Aug 28;4:19–19. doi: 10.1186/1471-2474-4-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Hanauer S. B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep;13 (Suppl 4):16–38. doi: 10.1046/j.1365-2036.1999.00027.x. [DOI] [PubMed] [Google Scholar]
  48. Hanauer Stephen B., Feagan Brian G., Lichtenstein Gary R., Mayer Lloyd F., Schreiber S., Colombel Jean Frederic, Rachmilewitz Daniel, Wolf Douglas C., Olson Allan, Bao Weihang. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4. [DOI] [PubMed] [Google Scholar]
  49. Harriman G., Harper L. K., Schaible T. F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I61–I64. doi: 10.1136/ard.58.2008.i61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Hassard P. V., Binder S. W., Nelson V., Vasiliauskas E. A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001 Mar;120(4):995–999. doi: 10.1053/gast.2001.22556. [DOI] [PubMed] [Google Scholar]
  51. Hochberg M. C., Tracy J. K., Hawkins-Holt M., Flores R. H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 (Suppl 2):ii13–ii16. doi: 10.1136/ard.62.suppl_2.ii13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hoffman Gary S., Merkel Peter A., Brasington Richard D., Lenschow Deborah J., Liang Patrick. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004 Jul;50(7):2296–2304. doi: 10.1002/art.20300. [DOI] [PubMed] [Google Scholar]
  53. Hull Keith M., Drewe Elizabeth, Aksentijevich Ivona, Singh Harjot K., Wong Kondi, McDermott Elizabeth M., Dean Jane, Powell Richard J., Kastner Daniel L. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002 Sep;81(5):349–368. doi: 10.1097/00005792-200209000-00002. [DOI] [PubMed] [Google Scholar]
  54. Husni M. Elaine, Maier Agnes L., Mease Philip J., Overman Steven S., Fraser Patricia, Gravallese Ellen M., Weinblatt Michael E. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002 May;46(5):1171–1176. doi: 10.1002/art.10231. [DOI] [PubMed] [Google Scholar]
  55. Jarvis B., Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 1999 Jun;57(6):945–966. doi: 10.2165/00003495-199957060-00014. [DOI] [PubMed] [Google Scholar]
  56. Jones R. E., Moreland L. W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999;48(3):1–4. [PubMed] [Google Scholar]
  57. Joseph Annie, Raj Dev, Dua Harminder S., Powell Pauline T., Lanyon Peter C., Powell Richard J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003 Jul;110(7):1449–1453. doi: 10.1016/S0161-6420(03)00406-8. [DOI] [PubMed] [Google Scholar]
  58. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  59. Kavanaugh Arthur, Han Chenglong, Bala Mohan. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May;31(5):849–855. [PubMed] [Google Scholar]
  60. Keane J., Gershon S., Wise R. P., Mirabile-Levens E., Kasznica J., Schwieterman W. D., Siegel J. N., Braun M. M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104. doi: 10.1056/NEJMoa011110. [DOI] [PubMed] [Google Scholar]
  61. Khanna Dinesh, Liebling Michael R., Louie James S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003 Aug;30(8):1864–1867. [PubMed] [Google Scholar]
  62. Khanna Dinesh, McMahon Maureen, Furst Daniel E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27(5):307–324. doi: 10.2165/00002018-200427050-00003. [DOI] [PubMed] [Google Scholar]
  63. Khanna M., Shirodkar M. A., Gottlieb A. B. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat. 2003 Dec;14(4):229–232. doi: 10.1080/09546630310020470. [DOI] [PubMed] [Google Scholar]
  64. Klareskog Lars, van der Heijde Désirée, de Jager Julien P., Gough Andrew, Kalden Joachim, Malaise Michel, Martín Mola Emilio, Pavelka Karel, Sany Jacques, Settas Lucas. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681. doi: 10.1016/S0140-6736(04)15640-7. [DOI] [PubMed] [Google Scholar]
  65. Kraetsch H. G., Antoni C., Kalden J. R., Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis. 2001 Nov;60 (Suppl 3):iii55–iii57. doi: 10.1136/ard.60.90003.iii55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Kwon Hyon J., Coté Timothy R., Cuffe Michael S., Kramer Judith M., Braun M. Miles. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–811. doi: 10.7326/0003-4819-138-10-200305200-00008. [DOI] [PubMed] [Google Scholar]
  67. Lee Jong-Hoon, Slifman Nancy R., Gershon Sharon K., Edwards Evelyne T., Schwieterman William D., Siegel Jeffrey N., Wise Robert P., Brown S. Lori, Udall John N., Jr, Braun M. Miles. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–2570. doi: 10.1002/art.10583. [DOI] [PubMed] [Google Scholar]
  68. Leonardi Craig L., Powers Jerold L., Matheson Robert T., Goffe Bernard S., Zitnik Ralph, Wang Andrea, Gottlieb Alice B., Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. doi: 10.1056/NEJMoa030409. [DOI] [PubMed] [Google Scholar]
  69. Licata G., Pinto A., Tuttolomondo A., Banco A., Ciccia F., Ferrante A., Triolo G. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis. 2003 Mar;62(3):280–281. doi: 10.1136/ard.62.3.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  71. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. doi: 10.1056/NEJM200003163421103. [DOI] [PubMed] [Google Scholar]
  72. Lovell Daniel J., Giannini Edward H., Reiff Andreas, Jones Olcay Y., Schneider Rayfel, Olson Judyann C., Stein Leonard D., Gedalia Abraham, Ilowite Norman T., Wallace Carol A. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan;48(1):218–226. doi: 10.1002/art.10710. [DOI] [PubMed] [Google Scholar]
  73. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  74. Manadan A. M., Block J. A., Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol. 2003 Jul-Aug;21(4):526–526. [PubMed] [Google Scholar]
  75. Mangge Harald, Heinzl Bernd, Grubbauer Hans-Michael, El-Shabrawi Yosuf, Schauenstein Konrad. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int. 2003 Apr 10;23(5):258–261. doi: 10.1007/s00296-003-0308-1. [DOI] [PubMed] [Google Scholar]
  76. Mariette Xavier, Ravaud Philippe, Steinfeld Serge, Baron Gabriel, Goetz Joelle, Hachulla Eric, Combe Bernard, Puéchal Xavier, Pennec Yvon, Sauvezie Bernard. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004 Apr;50(4):1270–1276. doi: 10.1002/art.20146. [DOI] [PubMed] [Google Scholar]
  77. Markham A., Lamb H. M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000 Jun;59(6):1341–1359. doi: 10.2165/00003495-200059060-00010. [DOI] [PubMed] [Google Scholar]
  78. McMinn J. R., Jr, Cohen Stephen, Moore Joseph, Lilly Scott, Parkhurst Joan, Tarantino Michael D., Terrell Deirdra R., George James N. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol. 2003 Jun;73(2):135–140. doi: 10.1002/ajh.10331. [DOI] [PubMed] [Google Scholar]
  79. Mease P. J. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1–4. [PubMed] [Google Scholar]
  80. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  81. Mease Philip J., Kivitz Alan J., Burch Francis X., Siegel Evan L., Cohen Stanley B., Ory Peter, Salonen David, Rubenstein Joel, Sharp John T., Tsuji Wayne. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272. doi: 10.1002/art.20335. [DOI] [PubMed] [Google Scholar]
  82. Mohan N., Edwards E. T., Cupps T. R., Oliverio P. J., Sandberg G., Crayton H., Richert J. R., Siegel J. N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–2869. doi: 10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  83. Moreland L. W., Margolies G., Heck L. W., Jr, Saway A., Blosch C., Hanna R., Koopman W. J. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855. [PubMed] [Google Scholar]
  84. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  85. Naveau Sylvie, Chollet-Martin Sylvie, Dharancy Sébastien, Mathurin Philippe, Jouet Pauline, Piquet Marie-Astrid, Davion Thierry, Oberti Frédéric, Broët Philippe, Emilie Dominique. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390–1397. doi: 10.1002/hep.20206. [DOI] [PubMed] [Google Scholar]
  86. Ogilvie A. L., Antoni C., Dechant C., Manger B., Kalden J. R., Schuler G., Lüftl M. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001 Mar;144(3):587–589. doi: 10.1046/j.1365-2133.2001.04089.x. [DOI] [PubMed] [Google Scholar]
  87. Peterson J. R., Hsu F. C., Simkin P. A., Wener M. H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003 Nov;62(11):1078–1082. doi: 10.1136/ard.62.11.1078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Prior P., Symmons D. P., Hawkins C. F., Scott D. L., Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis. 1984 Apr;43(2):128–131. doi: 10.1136/ard.43.2.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Rozenbaum M., Rosner I., Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002 Mar;61(3):283–284. doi: 10.1136/ard.61.3.283-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Salvarani Carlo, Cantini Fabrizio, Olivieri Ignazio, Macchioni Pierluigi, Padula Angela, Niccoli Laura, Catanoso Maria Grazia, Scocco Giovanni Lo, Boiardi Luigi. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003 Aug 15;49(4):541–545. doi: 10.1002/art.11201. [DOI] [PubMed] [Google Scholar]
  91. Sankar Vidya, Brennan Michael T., Kok Marc R., Leakan Rose Anne, Smith Janine A., Manny Joan, Baum Bruce J., Pillemer Stanley R. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004 Jul;50(7):2240–2245. doi: 10.1002/art.20299. [DOI] [PubMed] [Google Scholar]
  92. Saulsbury Frank T., Mann James A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003 Aug 15;49(4):599–600. doi: 10.1002/art.11204. [DOI] [PubMed] [Google Scholar]
  93. Scheinfeld Noah. Adalimumab (HUMIRA): a review. J Drugs Dermatol. 2003 Aug;2(4):375–377. [PubMed] [Google Scholar]
  94. Schiemann U., Kellner H. Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen. Z Gastroenterol. 2002 Nov;40(11):937–943. doi: 10.1055/s-2002-35412. [DOI] [PubMed] [Google Scholar]
  95. Sfikakis P. P. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002 Nov;61 (Suppl 2):ii51–ii53. doi: 10.1136/ard.61.suppl_2.ii51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., Kaklamanis P., Markomichelakis N. N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001 Jul 28;358(9278):295–296. doi: 10.1016/s0140-6736(01)05497-6. [DOI] [PubMed] [Google Scholar]
  97. Shekelle P. G., Woolf S. H., Eccles M., Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999 Feb 27;318(7183):593–596. doi: 10.1136/bmj.318.7183.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Slifman Nancy R., Gershon Sharon K., Lee Jong-Hoon, Edwards Evelyne T., Braun M. Miles. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–324. doi: 10.1002/art.10758. [DOI] [PubMed] [Google Scholar]
  99. Smolen J. S., Breedveld F. C., Schiff M. H., Kalden J. R., Emery P., Eberl G., van Riel P. L., Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003 Feb;42(2):244–257. doi: 10.1093/rheumatology/keg072. [DOI] [PubMed] [Google Scholar]
  100. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589–593. [PubMed] [Google Scholar]
  101. Spahr Laurent, Rubbia-Brandt Laura, Frossard Jean-Loius, Giostra Emile, Rougemont Anne-Laure, Pugin Jérôme, Fischer Maria, Egger Hanspeter, Hadengue Antoine. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002 Oct;37(4):448–455. doi: 10.1016/s0168-8278(02)00230-1. [DOI] [PubMed] [Google Scholar]
  102. Steinfeld S. D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001 Oct;44(10):2371–2375. doi: 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  103. Takada Kazuki, Aksentijevich Ivona, Mahadevan Vijayabhanu, Dean Jane A., Kelley Richard I., Kastner Daniel L. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 2003 Sep;48(9):2645–2651. doi: 10.1002/art.11218. [DOI] [PubMed] [Google Scholar]
  104. Tan A. L., Holdsworth J., Pease C., Emery P., McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003 Apr;62(4):373–374. doi: 10.1136/ard.62.4.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Tutrone William D., Saini Rita, Weinberg Jeffery M. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept. IDrugs. 2004 Jan;7(1):45–49. [PubMed] [Google Scholar]
  106. Utz James P., Limper Andrew H., Kalra Sanjay, Specks Ulrich, Scott John P., Vuk-Pavlovic Zvezdana, Schroeder Darrell R. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003 Jul;124(1):177–185. doi: 10.1378/chest.124.1.177. [DOI] [PubMed] [Google Scholar]
  107. Van Den Bosch Filip, Kruithof Elli, Baeten Dominique, Herssens Annemie, de Keyser Filip, Mielants Herman, Veys Eric M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002 Mar;46(3):755–765. doi: 10.1002/art.511. [DOI] [PubMed] [Google Scholar]
  108. Wallis R. S., Broder M. S., Wong J. Y., Hanson M. E., Beenhouwer D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 Apr 15;38(9):1261–1265. doi: 10.1086/383317. [DOI] [PubMed] [Google Scholar]
  109. Weiss Jennifer E., Eberhard B. Anne, Chowdhury Devyani, Gottlieb Beth S. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004 Apr;31(4):808–810. [PubMed] [Google Scholar]
  110. Whiting-O'Keefe Q. E., Fye K. H., Sack K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991 Jun;90(6):711–716. [PubMed] [Google Scholar]
  111. Willkens R. F., Williams H. J., Ward J. R., Egger M. J., Reading J. C., Clements P. J., Cathcart E. S., Samuelson C. O., Jr, Solsky M. A., Kaplan S. B. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376–381. doi: 10.1002/art.1780270403. [DOI] [PubMed] [Google Scholar]
  112. Wolfe F., Pincus T., O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol. 2001 Jul;28(7):1712–1717. [PubMed] [Google Scholar]
  113. van Vollenhoven R. F., Brannemark S., Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis. 2004 Apr;63(4):426–430. doi: 10.1136/ard.2003.010967. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES